Your browser doesn't support javascript.
loading
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee, Choong-Kun; Chon, Hong Jae; Cheon, Jaekyung; Lee, Myung Ah; Im, Hyeon-Su; Jang, Joung-Soon; Kim, Min Hwan; Park, Sejung; Kang, Beodeul; Hong, Moonki; Kim, Jin Won; Park, Hyung Soon; Kang, Myoung Joo; Park, Young Nyun; Choi, Hye Jin.
Afiliação
  • Lee CK; Division of Medical Oncology, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, South Korea; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
  • Chon HJ; Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Centre, CHA University, Seongnam, South Korea.
  • Cheon J; Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Centre, CHA University, Seongnam, South Korea; Department of Haematology and Oncology, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, South Korea.
  • Lee MA; Division of Medical Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul St Mary's Hospital, Seoul, South Korea.
  • Im HS; Department of Haematology and Oncology, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, South Korea.
  • Jang JS; Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.
  • Kim MH; Division of Medical Oncology, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, South Korea.
  • Park S; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
  • Kang B; Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Centre, CHA University, Seongnam, South Korea.
  • Hong M; Division of Medical Oncology, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim JW; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
  • Park HS; Division of Medical Oncology, St Vincent's Hospital, The Catholic University of Korea, Seoul, South Korea.
  • Kang MJ; Department of Oncology, Inje University Haeundae Paik Hospital, Busan, South Korea.
  • Park YN; Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea.
  • Choi HJ; Division of Medical Oncology, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: choihj@yuhs.ac.
Lancet Gastroenterol Hepatol ; 8(1): 56-65, 2023 Jan.
Article em En | MEDLINE | ID: mdl-36328033
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Neoplasias do Sistema Biliar / Colangiocarcinoma Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Neoplasias do Sistema Biliar / Colangiocarcinoma Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article